Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.79 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083271 | 0.91 | OXTR (0.83) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL4942430 | 0.91 | OXTR (0.83) | OXTRAVPR1AROCK2ROCK1FFAR2 | |
| SCHEMBL4945458 | 0.91 | OXTR (0.83) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL7089781 | 0.88 | OXTR (0.75) | OXTRAVPR1AROCK2ROCK1FFAR2 | |
| SCHEMBL4944776 | 0.88 | OXTR (1.00) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL4936262 | 0.88 | OXTR (1.00) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL4936835 | 0.88 | OXTR (1.00) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL4945256 | 0.88 | OXTR (1.00) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL4945247 | 0.88 | OXTR (1.00) | OXTRAVPR1AROCK2ROCK1ADRB1 | |
| SCHEMBL4944386 | 0.88 | OXTR (1.00) | OXTRAVPR1AROCK2ROCK1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | OXTR 189/4885AVPR1A 1456/4885ROCK2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.